Lobbying Information
Subject Matters
- Aboriginal Affairs
- Health
- Industry
- Intellectual Property
- Internal Trade
- International Relations
- International Trade
- Justice and Law Enforcement
- Regional Development
- Research and Development
- Science and Technology
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Legislative Proposal, Policy or Program Canada's Food and Consumer Safety Action Plan, specifically proposed legislation and regulation with respect to strengthening the safety of drug products/therapeutic products in the Food and Drug Regulations
- Patent Act as it relates to the regulation of intellectual property for therapeutic products
Legislative Proposal, Bill or Resolution, Policies or Program
- Comprehensive Economic and Trade Agreement Negotiations as it related to the protection of intellectual property rights.
Legislative Proposal, Bill or Resolution, Regulation
- Food and Drugs Act Regulations, specifically with respect to approval, regulation and life-cycle management of therapeutic products
Policies or Program
- Federal public drug plans, specifically the Non-Insured Health Benefits Program (Health Canada), with respect to decisions and policies that impact reimbursement of therapeutic products for plan beneficiaries
- Health Canada Blueprint for Renewal: Modernizing Regulatory System for Health Products and Food (formerly Bill C-51)
- Policy or program: Federal Health Partnership with respect to the coordination of federal drug plan policies and programs
- Research and Development Legislative Proposal, Policy or Program, with respect to the strategy on innovation.
- Science and Technology Strategy led by Industry Canada, particularly with respect to the life sciences priority under the S&T Strategy
Policies or Program, Regulation
- Patented Medicines Prices Review Board with respect to amendments to the guidelines for the regulation of pricing of patented drug products patentees
- Patented Medicines Prices Review Board with respect to decisions on the reporting obligations of patented drug products patentees
Regulation
- Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations.
Communication Techniques
-
Written communication
-
Oral communication
-
Grass-roots communication
-
Meetings, presentations and telephone communication
Government Institutions
-
Aboriginal Affairs and Northern Development Canada
-
Atlantic Canada Opportunities Agency (ACOA)
-
Federal Office of Regional Development – Quebec (FORD[Q])
-
Finance Canada (FIN)
-
Foreign Affairs and International Trade Canada (DFAITC)
-
Health Canada (HC)
-
House of Commons
-
Human Resources and Social Development Canada (HRSDC)
-
Industry Canada
-
Justice Canada (JC)
-
Members of the House of Commons
-
National Defence (DND)
-
National Research Council (NRC)
-
Natural Resources Canada (NRCan)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Works and Government Services Canada
-
Senate of Canada
-
Veterans Affairs Canada (VAC)
-
Western Economic Diversification Canada (WD)
In-house Corporation Details
Description of activities
Innovative pharmaceutical company - marketing and sales of drugs, medical devices, natural health products, cosmetics and offer of therapeutic solutions.
Responsible officer name and position during the period of this registration
Jonathan Fairest,
President and Chief Executive Officer (CEO)
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
2905 Place Louis-R. Renaud
Laval, QC H7V 0A3
Canada
Telephone number:
514-331-9220
Parent Company Information
- Sanofi
-
54 rue de la Boétie
Paris 75008
France
Subsidiary Beneficiary Information
- Sanofi Consumer Health Inc. / Sanofi Santé Grand Public Inc.
-
2905 Place Louis-R. Renaud
Laval, QC H7V 0A3
Canada
- sanofi-Pasteur Ltd.
-
1755 Steeles Avenue
Toronto, ON M2R 3T4
Canada
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Jonathan Fairest,
President & CEO |
No public offices held
- Richard Grégoire,
Vice-president, Evidence, Value and Access |
No public offices held
- Franca Mancino,
Vice-president, Medical and Regulatory Affairs |
No public offices held
- Robert Quesnel,
Vice-president, Legal and Corporate Affairs |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Michel G. Tremblay,
Director, Federal Affairs |
No public offices held
